

# Carlo Vitagliano

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7349506/publications.pdf>

Version: 2024-02-01

11  
papers

417  
citations

933447

10  
h-index

1281871

11  
g-index

11  
all docs

11  
docs citations

11  
times ranked

830  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic Value of Cancer Stem Cells Markers in Triple-Negative Breast Cancer. <i>BioMed Research International</i> , 2015, 2015, 1-10.	1.9	87
2	Vorinostat synergizes with EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation of the major mitochondrial porin VDAC1 and modulation of the c-Myc-NRF2-KEAP1 pathway. <i>Free Radical Biology and Medicine</i> , 2015, 89, 287-299.	2.9	73
3	Valproic acid potentiates the anticancer activity of capecitabine <i>in vitro</i> and <i>in vivo</i> in breast cancer models via induction of thymidine phosphorylase expression. <i>Oncotarget</i> , 2016, 7, 7715-7731.	1.8	67
4	Golgi maturation-dependent glycoenzyme recycling controls glycosphingolipid biosynthesis and cell growth via GOLPH3. <i>EMBO Journal</i> , 2021, 40, e107238.	7.8	45
5	A standardized flow cytometry network study for the assessment of circulating endothelial cell physiological ranges. <i>Scientific Reports</i> , 2018, 8, 5823.	3.3	38
6	Synergistic antitumor interaction of valproic acid and simvastatin sensitizes prostate cancer to docetaxel by targeting CSCs compartment via YAP inhibition. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 213.	8.6	26
7	Valproic Acid Synergizes With Cisplatin and Cetuximab <i>in vitro</i> and <i>in vivo</i> in Head and Neck Cancer by Targeting the Mechanisms of Resistance. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 732.	3.7	22
8	Synergistic antitumor activity of histone deacetylase inhibitors and anti-ErbB3 antibody in NSCLC primary cultures via modulation of ErbB receptors expression. <i>Oncotarget</i> , 2016, 7, 19559-19574.	1.8	20
9	HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 83.	8.6	19
10	Synthesis and Evaluation of the Antitumor Properties of a Small Collection of Pt <sup>II</sup> Complexes with 7-Deazaadenosine as Scaffold. <i>European Journal of Organic Chemistry</i> , 2017, 2017, 4935-4947.	2.4	10
11	Randomized phase II study of valproic acid in combination with bevacizumab and oxaliplatin/fluoropyrimidine regimens in patients with <i>RAS</i> -mutated metastatic colorectal cancer: the REVOLUTION study protocol. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592092958.	3.2	10